GSM gold starGSM Global
中文版 · Chinese

Johnson & Johnson to Acquire Ollin for $2.2 Billion Upfront, Adding Phase 3 Eye Antibody OLN324; Blackstone to Fund Development With $750 Million

Monday, November 16, 2026 · Finance · GSM News

Johnson & Johnson announced in New Brunswick, New Jersey, on November 16 that it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for $2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments of up to approximately $1.125 billion.

The acquisition would add OLN324 to Johnson & Johnson's pipeline, a Phase 3 investigational bispecific antibody designed to target two key pathways in retinal diseases, vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2). OLN324 is being developed for retinal vascular diseases including wet age-related macular degeneration and diabetic macular edema, which together affect more than 40 million people worldwide and are leading causes of vision loss. Johnson & Johnson said OLN324 is a next-generation antibody with high Ang2 potency and a small protein format that could enable improved control of retinal fluid.

"OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control," said Kip Connor, Vice President and Ophthalmology Disease Area Stronghold Leader at Johnson & Johnson, adding that the data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments.

Under a separate development funding agreement, Blackstone Life Sciences will pay a total of $750 million to Johnson & Johnson over multiple years to fully fund the Phase 3 development of OLN324, contingent upon the acquisition closing. In return, Blackstone will be eligible to receive certain regulatory and sales milestone payments as well as single-digit royalties.

Johnson & Johnson expects the transaction to close before the end of 2026, subject to applicable regulatory approvals and customary closing conditions, and said the accounting treatment will be communicated on or before the close. According to Ollin's own June announcement, the company had closed a $330 million Series B financing, and OLN324 had shown faster and greater retinal drying than faricimab in a 164-patient head-to-head proof-of-concept study, with global Phase 3 trials planned to start in the second half of 2026.

Related: Johnson & Johnson Phase 1 results: pasritamig plus JNJ-9401 posts 73% PSA response rate in advanced prostate cancer

(Source: Johnson & Johnson)

Source: Johnson & Johnson

Published by GSM · USA (original Chinese edition)

Photo: 图:强生公司位于新泽西州 New Brunswick 的总部入口标识。ajay_suresh 摄,CC BY 4.0,经 Wikimedia Commons。 / Photo: Entrance sign at Johnson & Johnson headquarters in New Brunswick, New Jersey. By ajay_suresh, CC BY 4.0, via Wikimedia Commons.

Latest in Finance